Sugi Predict

Sugi Predict / Compounds / Quinoxaline

Quinoxaline

Quinoxaline

SCHEMBL83382

c1c[nH]cn1.c1ccc2nccnc2c1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.56
▸ FKBP5 Q13451 1/20 0.56
▸ MAPK1 P28482 1/20 0.35
▸ NCF1 P14598 1/20 0.33
▸ METAP2 P50579 1/20 0.33
▸ KDM4E B2RXH2 4/20 0.32
▸ CCNB2 O95067 3/20 0.32
▸ CDK1 P06493 3/20 0.32
▸ CCNB1 P14635 3/20 0.32
▸ CDK5 Q00535 3/20 0.32
▸ CDK5R1 Q15078 3/20 0.32
▸ CCNB3 Q8WWL7 3/20 0.32
▸ MAPT P10636 3/20 0.32
▸ GSK3B P49841 2/20 0.32
▸ GSK3A P49840 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ USP2 O75604 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Imidazole SCHEMBL27749802 0.91 ALDH1A1 (0.56) ALDH1A1FKBP5KDM4EMAPTMEN1
Quinoxaline SCHEMBL28074971 0.91 ALDH1A1 (0.46) ALDH1A1FKBP5MAPK1METAP2CCNB2
Quinoxaline SCHEMBL28457376 0.86 ALDH1A1 (0.42) ALDH1A1FKBP5KDM4ECDK1CDK5
Quinoxaline SCHEMBL27809289 0.85 ALDH1A1 (0.41) ALDH1A1FKBP5SMN1; SMN2
Quinoxaline SCHEMBL29215386 0.85 ALDH1A1 (0.41) ALDH1A1FKBP5
Phenazine SCHEMBL28557583 0.84 ALDH1A1 (0.59) ALDH1A1FKBP5KDM4EMAPTMEN1
Quinoline SCHEMBL27685815 0.84 ALDH1A1 (0.63) ALDH1A1FKBP5KDM4EMAPTMEN1
Quinoline SCHEMBL2029469 0.84 ALDH1A1 (0.63) ALDH1A1FKBP5KDM4EMAPTMEN1
Quinoline SCHEMBL27877830 0.84 ALDH1A1 (0.63) ALDH1A1FKBP5KDM4EMAPTMEN1
Quinoline SCHEMBL27277627 0.84 ALDH1A1 (0.63) ALDH1A1FKBP5KDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 663 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024067311-A1 PHOTOELECTRIC DEVICE AND MANUFACTURING METHOD THEREFOR TCL科技集团股份有限公司 2024-04-04 — — WO claimed
CN-112018248-B Display device and preparation method thereof 固安鼎材科技有限公司 2023-12-29 — — CN claimed
WO-2023138254-A1 HETEROCYCLIC COMPOUND, AND ORGANIC ELECTROLUMINESCENT MATERIAL AND ELEMENT 上海八亿时空先进材料有限公司 2023-07-27 — — WO claimed
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2023-05-04 — — US claimed
US-20220249680-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2022-08-11 — — US claimed
EP-3986468-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES Synthis Therapeutics, Inc. (US) 2022-04-27 — — EP claimed
US-20220119270-A1 CERIA NANOPARTICLES AND CERIA NANOPARTICLES PREPARATION METHOD Research & Business Foundation Sungkyunkwan University (KR) 2022-04-21 — — US claimed
CN-114269388-A antibody-ALK 5 inhibitor conjugates and uses thereof 辛瑟斯治疗股份有限公司 2022-04-01 — — CN claimed
US-20210299268-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS THERAPEUTICS, INC. (US) 2021-09-30 — — US claimed
CN-113382754-A Compounds, compositions, methods and uses for treating cancer and immune disorders IL-2RX公司 2021-09-10 — — CN claimed
EP-3820467-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES Synthis Therapeutics, Inc. (US) 2021-05-19 — — EP claimed
EP-3820533-A2 COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS IL-2RX, Inc. (US) 2021-05-19 — — EP claimed
CN-112601522-A antibody-ALK 5 inhibitor conjugates and uses thereof 辛瑟斯治疗股份有限公司 2021-04-02 — — CN claimed
WO-2020256721-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-12-24 — — WO claimed
WO-2020256751-A1 ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-12-24 — — WO claimed
US-20200147234-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES SYNTHIS, LLC (US) 2020-05-14 — — US claimed
CN-106715420-A crosslinkable host material 西诺拉股份有限公司 2017-05-24 — — CN claimed
CN-106084187-A Polymer, crosslinked polymer and the electroluminescent device comprising described polymer 默克专利有限公司 2016-11-09 — — CN claimed
CN-104072500-A 2,3-dibenzylamine quinoxaline imidazole onium salt and synthesis method thereof UNIV JIANGSU 2014-10-01 — — CN claimed
US-4283488-A SILVER HALIDE EMULSIONS EASTMAN KODAK COMPANY (US) 1981-08-11 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220249680-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 ALDH1A1 346/4885FKBP5 2436/4885MAPK1 3743/4885
US-20210299268-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 ALDH1A1 346/4885FKBP5 2436/4885MAPK1 3743/4885
US-20200147234-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 ALDH1A1 346/4885FKBP5 2436/4885MAPK1 3743/4885
US-20230132568-A1 ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES ALK, ALKBH5, ALKBH3 ALDH1A1 346/4885FKBP5 2436/4885MAPK1 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.